JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) 10-Year Sharpe Ratio: N/A (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BKK:JSP-R JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
82 GF Score
Price ฿1.75
GF Value ฿2.18
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is JSP Pharmaceutical Manufacturing (Thailand) PCL 10-Year Sharpe Ratio?

The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-08-31), JSP Pharmaceutical Manufacturing (Thailand) PCL's 10-Year Sharpe Ratio is Not available.

JSP Pharmaceutical Manufacturing (Thailand) PCL  (BKK:JSP-R) 10-Year Sharpe Ratio Explanation

The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

JSP Pharmaceutical Manufacturing (Thailand) PCL 10-Year Sharpe Ratio Related Terms

BKK:JSP-R vs KHC, GIS: 10-Year Sharpe Ratio Comparison

For the Packaged Foods subindustry, JSP Pharmaceutical Manufacturing (Thailand) PCL's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JSP Pharmaceutical Manufacturing (Thailand) PCL 10-Year Sharpe Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, JSP Pharmaceutical Manufacturing (Thailand) PCL's 10-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where JSP Pharmaceutical Manufacturing (Thailand) PCL's 10-Year Sharpe Ratio falls into.


BKK:JSP-R
82GF Score
JSP Pharmaceutical Manufacturing (Thailand) PCL BKK:JSP-R
10-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JSP Pharmaceutical Manufacturing (Thailand) PCL 10-Year Sharpe Ratio Calculation

The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.

Is JSP Pharmaceutical Manufacturing (Thailand) PCL (BKK:JSP-R) Overvalued in 2026?

Based on GuruFocus' analysis, JSP Pharmaceutical Manufacturing (Thailand) PCL stock appears to be undervalued. The current stock price of ฿1.75 is trading 19.9% below its estimated GF Value™ of ฿2.18. GuruFocus considers JSP Pharmaceutical Manufacturing (Thailand) PCL to be Modestly Undervalued.

Key valuation signals for BKK:JSP-R:

  • 10-Year Sharpe Ratio: N/A
  • GF Value™: ฿2.18 vs. price of ฿1.75 (19.9% below fair value)
  • GF Score™: 82/100 with 7 warning signs

No single metric tells the full story. See the BKK:JSP-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JSP Pharmaceutical Manufacturing (Thailand) PCL Business Description

Other Exchanges JSP:Thailand
Address No. 255, 257 Soi Sathupradit 58, Bang Pongphang, Yan Nawa, Bangkok, THA, 10120
JSP Pharmaceutical Manufacturing (Thailand) PCL is engaged in producing modern medicine, traditional medicine, herbal products, dietary supplements, medical supplies, and cleaning alcohol under the client's and the company's own trademarks. Maximum revenue for the company is generated from the sale of dietary supplements. The Group's reportable operating segments are: Manufacture and distribution of products under the company's brand name (Own brands), which generate maximum revenue, Manufacture and distribution of products under customers' brand name (OEM), Manufacture and distribution of hemodialysis solution and related medical supplies; and Service, research and development, and healthcare products training. Geographically, it operates principally in Thailand.
82GF Score

Get the complete analysis for BKK:JSP-R

10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿1.75
Price
฿2.18
GF Value